 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1988 (as Molecular Vaccines, Inc.) 1989 (as MedImmune, Inc.) |
| Headquarters | Gaithersburg, Maryland, U.S. |
| Products | Synagis FluMist |
| Parent | AstraZeneca |
| Website | www.medimmune.com[dead link] |
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.[1][2]
MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion.[3] Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA.[4]
It produced Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune acquired FluMist when it purchased Aviron in 2002 for US$ 1.5 billion. FluMist sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006.[5]
FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.[6]
MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration (FDA) in 2007, and is now the form offered on the market.
- ^ "12 years on, Astra draws a line under Medimmune". Evaluate.com. 2019-02-14. Retrieved 2019-02-15.
- ^ "AstraZeneca retires Medimmune name amid sales turnaround". BioPharma Dive. Retrieved 2019-02-16.
- ^ Pollack, Andrew (24 April 2007). "AstraZeneca Buys MedImmune for $15.6 Billion". Retrieved 2 June 2019 – via NYTimes.com.
- ^ "About Us | MedImmune". Archived from the original on 2017-08-30. Retrieved 2017-08-23.
- ^ Michael S. Rosenwald (June 2, 2009). "MedImmune Wins Key Contract To Develop Swine Flu Vaccine". The Washington Post. Retrieved October 23, 2009.
- ^
- Medimmune Company Site
- Flumist nasal flu vaccine - Official website
- Bishop, Tricia. "MedImmune loss in '05 quadruples shortfall from '04" Baltimore Sun. 3 February 2006.
- Rosenwald, Michael S. "Sales of MedImmune's Flu Vaccine Drop Sharply" Washington Post. 3 February 2006.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search